From the posts above, this continues to sound underwhelming, especially:
I think there is a much more plausible explanation for anti-ACE2 antibodies. Anti-idiotype antibodies can be made against monoclonal therapeutic antibodies but the evidence for them being made to natural polyclonal...
I am not sure what you are meaning here and the analogy with allergy does not seem quite relevant.
What are being looked for are gene variants. If these gene variants are more common in people with anxiety and people with anxiety are more likely to report IBS then any apparent link between the...
Countless investigations were carried out with DualDur, while carefully observing and recording clinical symptoms, and performing 110,000 serological tests to back up the diagnosis.
That sounds like money talking, not a scientific lab.
There are no publications on PubMed mentioning DualDur in...
It looks as if the UK Biobank data replicated findings from 23&Me? But yes, there is a problem here.
If these genes not turn up for ME/CFS that might be something very important.
A link to anxiety is pretty much bound to occur with 'IBS'. I suspect almost anyone with significant anxiety...
I think the explanation starts to get too complicated. William of Ockham would disapprove.
If sagging blood pressure is important, which it might be, we don't really need to suggest clots or slow red cells as well If there are clots then sagging blood pressure probably wouldn't make much...
I have not read published papers on this but my instinct is that it is a laboratory artefact, because:
1. The plasma samples appear to have undergone freezing and thawing, centrifugation and maybe 'trypsinisation', although that sounds like a confusion by a journalist. The clot shown is over...
I would go further. This looks to me like very irresponsible talk about something that is likely to turn out to be an artefact.
There is no excuse for doing anything other than properly controlled studies. Especially if coagulation is involved. The risks are very high in both directions.
It...
I would expect a micro clot in the circulation to last for maybe a minute or two at most. So I find it hard to see the point of some brief aphaeresis sessions for a condition lasting months.
There is a webpage on that under 'Guidelines in Practice. It has a caution about exercise and mentions the NICE guideline for ME but otherwise it is pretty much the same old, same old BPS-style 'holistic' approach with talking therapies and advice from physios on exercising back to health...
I have sympathy for someone ho has developed Post Covid problems and a medical professional may have useful insight from experiencing an illness but their conclusions are not necessarily entirely helpful.
The ida of a GP managing a problem with help from a multidisciplinary tam sounds like the...
I wouldn't subject anyone to apheresis other than in a very well designed trial.
I haven't looked at this in detail but it sounds like bad science from what people are posting.
I think it will have a very big impact on the process of reaching an assessment. The problems with the Larun review were well known but the guideline makes them official in a way that means that to revert to the Larun conclusion would require very clear justification.
It will be an open test of...
My understanding is that the point of the experiment as to assess the impedance of the cell membranes, not the solution. However, I never understood from the description how they knew what they were measuring.
I cannot see any particular reason why macromolecular aggregation should also the...
Just take every opportunity that comes, I think.
The guideline process and the round table got a message across to some new people. I try to get the message across to HealthWatch and through the media when asked.
I suspect the most productive route for patients is as lay representatives on...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.